ストックスクリーナーアプリを入手
80.82
2.12%
1.68
アフターアワーズ：
80.99
0.17
+0.21%
前日終値:
$79.14
開ける：
$79.19
24時間の取引高:
1.47M
Relative Volume:
0.62
時価総額：
$13.09B
収益：
$705.14M
当期純損益:
$-453.90M
株価収益率:
-26.59
EPS:
-3.04
ネットキャッシュフロー:
$-551.29M
1週間 パフォーマンス:
-1.05%
1か月 パフォーマンス:
+11.22%
6か月 パフォーマンス:
+126.90%
1年 パフォーマンス:
+118.37%
1日の値動き範囲:
$78.50
$80.92
1週間の範囲:
$77.79
$82.86
52週間の値動き範囲:
$23.95
$83.61
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
名前
Ionis Pharmaceuticals Inc
セクター
電話
(760) 931-9200
住所
2855 GAZELLE COURT, CARLSBAD, CA
IONS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
80.82 | 12.82B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-09-26 | アップグレード | Goldman | Sell → Neutral |
| 2025-09-03 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | アップグレード | Barclays | Equal Weight → Overweight |
| 2025-04-07 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Neutral |
| 2024-08-02 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 再開されました | Jefferies | Buy |
| 2024-06-14 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-10-23 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 開始されました | Raymond James | Strong Buy |
| 2023-07-31 | アップグレード | Citigroup | Neutral → Buy |
| 2023-06-07 | 再開されました | Piper Sandler | Overweight |
| 2023-05-04 | アップグレード | Citigroup | Sell → Neutral |
| 2023-03-21 | 開始されました | Bernstein | Underperform |
| 2022-12-21 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 再開されました | Morgan Stanley | Overweight |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2022-03-31 | 再開されました | Piper Sandler | Overweight |
| 2022-03-01 | 開始されました | Citigroup | Sell |
| 2022-03-01 | 開始されました | Guggenheim | Buy |
| 2022-02-01 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-12-14 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | アップグレード | UBS | Sell → Neutral |
| 2021-03-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 開始されました | UBS | Sell |
| 2020-12-15 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-09-14 | 再開されました | JP Morgan | Neutral |
| 2020-09-02 | 開始されました | The Benchmark Company | Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Outperform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-12-13 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-11-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 繰り返されました | Stifel | Hold |
| 2018-08-07 | 繰り返されました | Stifel | Hold |
| 2018-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 再開されました | Goldman | Sell |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-08-09 | 繰り返されました | Stifel | Hold |
| 2017-03-10 | ダウングレード | Goldman | Neutral → Sell |
| 2016-12-28 | 繰り返されました | BMO Capital Markets | Outperform |
| 2016-12-27 | 繰り返されました | Leerink Partners | Mkt Perform |
すべてを表示
Ionis Pharmaceuticals Inc (IONS) 最新ニュース
Ionis Pharmaceuticals Sees Rapid Rise On RNA Drug Progress - Finimize
B of A Securities Maintains Ionis Pharmaceuticals (IONS) Buy Recommendation - Nasdaq
Ionis Pharmaceuticals (IONS) Price Target Raised by B of A Securities | IONS Stock News - GuruFocus
Angioedema Pipeline 2025: FDA Approvals and Clinical Trials - openPR.com
450,254 Shares in Ionis Pharmaceuticals, Inc. $IONS Acquired by Norges Bank - MarketBeat
Polycythemia Vera Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharm - Barchart.com
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com
Can Ionis Pharmaceuticals Stock Hold Up When Markets Turn? - Trefis
Has Ionis Pharmaceuticals Run Too Far After 135% Surge and Bullish DCF Outlook? - Yahoo Finance
Ionis Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
How Twin FDA Breakthrough Therapy Wins Could Impact Ionis Pharmaceuticals (IONS) Investors - Sahm
Kennedy Capital Management LLC Has $5.22 Million Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Hsbc Holdings PLC Purchases 33,461 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Capital Fund Management S.A. Sells 26,795 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) Director Sells $2,262,960.00 in Stock - MarketBeat
Rx Rundown: Bristol Myers Squibb, Retro Bio, Ionis Pharmaceuticals and more - Medical Marketing and Media
Is Ionis Pharmaceuticals Inc. (ISI) stock suitable for passive index fundsEarnings Growth Summary & Accurate Entry/Exit Alerts - Newser
What Does the Market Think About Ionis Pharmaceuticals Inc? - Benzinga
Is Ionis Pharmaceuticals Inc. (ISI) stock undervalued after correctionJuly 2025 Catalysts & Weekly High Momentum Picks - Newser
Is Ionis Pharmaceuticals Inc. (ISI) stock attractive post correctionFed Meeting & Weekly High Return Stock Forecasts - Newser
How Ionis Pharmaceuticals Inc. (ISI) stock compares with tech leadersMarket Activity Summary & Community Consensus Stock Picks - Newser
Ionis Pharmaceuticals Earnings Notes - Trefis
Ionis Pharmaceuticals stock hits 52-week high at 82.97 USD By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals stock hits 52-week high at 82.97 USD - Investing.com
Ionis Pharmaceuticals stock maintains Buy rating at TD Cowen on growth outlook - Investing.com Canada
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows - Sahm
FDA grants breakthrough therapy status to Ionis’ Alexander disease drug By Investing.com - Investing.com Canada
Granite Investment Partners LLC Trims Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Why Ionis Pharmaceuticals Inc. (ISI) stock could break out in 2025July 2025 Pullbacks & Daily Volume Surge Trade Alerts - Newser
American Century Companies Inc. Raises Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
How robust is Ionis Pharmaceuticals Inc. (ISI) stock financial position - Newser
What hedge fund activity signals for Ionis Pharmaceuticals Inc. stock2025 Bull vs Bear & Consistent Income Trade Recommendations - Newser
Ionis gets FDA breakthrough therapy status for zilganersen - MSN
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 52-Week HighStill a Buy? - MarketBeat
Ionis Pharmaceuticals (IONS) Gains FDA Breakthrough Therapy Desi - GuruFocus
FDA Grants Breakthrough Therapy Status to Ionis Pharmaceuticals' Zilganersen (IONS) - GuruFocus
Ionis Pharmaceuticals' Investigational Alexander Disease Treatment Granted Breakthrough Therapy Designation - marketscreener.com
FDA grants breakthrough therapy status to Ionis’ Alexander disease drug - Investing.com
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD) - Business Wire
How Ionis Pharmaceuticals Inc. (ISI) stock performs during market turbulenceEntry Point & Low Risk Entry Point Tips - Newser
FDA grants breakthrough therapy status to Ionis’ olezarsen for severe HTG - Investing.com Australia
Ionis Pharmaceuticals (IONS): Valuation Perspective Following FDA Breakthrough Therapy Milestone for Olezarsen - Sahm
Ionis Pharmaceuticals (IONS): Valuation Insights Following FDA Breakthrough Therapy Status for Olezarsen - Yahoo Finance
Ionis Pharmaceuticals (IONS) Up 5.4% After EMA Nod and $700M Raise—Has the Bull Case Changed? - Yahoo Finance
Ionis receives U.S. FDA breakthrough therapy designation for olezarsen for severe hypertriglyceridemia - marketscreener.com
Ionis Says Olezarsen Gets FDA Breakthrough Therapy Designation for Severe Hypertriglyceridemia - marketscreener.com
FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuti - GuruFocus
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference - The Manila Times
Ionis Pharmaceuticals shares up 3.5% premarket after co receives FDA breakthrough therapy designation for olezarsen for SHTG - marketscreener.com
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG) - Business Wire
Ionis Pharmaceuticals Inc (IONS) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):